ArticleESC heart failure2026
Stratifying prognosis in heart failure patients with reduced ejection fraction and atrial cardiomyopathy.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimsCo-existence of atrial cardiomyopathy (AtCM) and heart failure with reduced ejection fraction (HFrEF) has prognostic implications. We aimed to quantify the association of a health records data biomarker, FIND-AF, with outcomes in patients with HFrEF and AtCM without atrial fibrillation (AF).
methodsPatients with HFrEF and AtCM without AF at baseline were identified from the ECG-HF registry (2010-6) and linked to the territory-wide Clinical Data Analysis and Reporting System. AtCM was operationalized using a pragmatic multi-domain framework based on the 2025 clinical consensus statement of the Heart Failure Association of the ESC, using electrocardiographic and echocardiographic parameters. Patients were stratified into high and low risk by sex-specific FIND-AF thresholds. The primary outcome was a composite of incident AF, ischaemic stroke, and all-cause mortality. All patients were followed until 31 December 2019.
resultsWe included 164 patients (mean age 62.3 ± 13.0 years, 73.8% men). The primary outcome occurred in 23/32 (71.9%) high-risk vs 67/132 (50.8%) low-risk patients (OR 2.48, 95% CI 1.07-5.76; P = .035). In the model including both FIND-AF risk group and AtCM severity, high FIND-AF risk remained associated with the composite outcome (adjusted OR 2.70, 95% CI 1.14-6.40; P = .024). Compared with CHA2DS2-VASc, FIND-AF showed superior discrimination for the composite outcome (AUC .735 vs .641; DeLong P = .007) and ischaemic stroke (AUC .700 vs .575; DeLong P = .008).
conclusionsHigh FIND-AF risk is associated with adverse prognosis in a cohort of patients with HFrEF and AtCM but without baseline AF. These exploratory data require external validation and a prospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.